邁瑞醫療(300760.SZ)一季度淨利增22.9%至31.6億元，國際三大業務線均實現快速增長
格隆匯4月26日丨邁瑞醫療(300760.SZ)公佈2024年第一季度報吿，報吿期營業收入為93.73億元，同比增長12.06%；歸屬於上市公司股東的淨利潤31.60億元，同比增長22.90%；歸屬於上市公司股東的扣除非經常性損益的淨利潤30.37億元，同比增長20.08%；經營活動產生的現金流量淨額28.65億元，同比增長114.85%，基本每股收益2.6107元。
公司繼續保證高研發投入，2024年第一季度研發投入10.30億元，佔營業收入的比重達到10.99%，產品不斷豐富，持續創新迭代，尤其在高端領域不斷實現突破。
由於去年同期國內重症病房建設所帶來的緊急採購需求量遠遠超過其他常規採購需求量，使得今年一季度國內市場整體在高基數的情況下實現了個位數增長，其中去年同期受抑制的國內體外診斷和醫學影像業務均實現了恢復性高速增長。因去年同期產能傾斜國內而導致國際市場基數較低，同時在海外高端客户羣突破持續加快的助力下，國際市場整體今年一季度增長近30%，其中發展中國家增長超過了30%，國際三大業務線均實現了快速增長。
展望今年，國內公立醫院的招投標活動預計呈現逐季度復甦的趨勢。鑑於去年上半年國內市場因緊急採購而導致公司基數墊高，而去年下半年的基數受行業整頓影響顯著降低，因此今年上下半年的收入增速預計會呈現不均衡的情況。但通過加快各項業務海內外高端客户羣突破和市場份額提升，以及抓住國內醫療新基建和設備更新項目的機會，公司對於完成全年的增長目標依然充滿信心。
未來，公司將繼續聚焦主業，全面加強產品研發創新、全球營銷拓展和海外本地化平台能力建設等多方面綜合能力，抓住全球重視醫療性價比、中國醫院進入高質量發展階段的歷史性機遇，加快突破海內外高端醫院和大型第三方連鎖實驗室，持續提升公司的產品競爭力和市場滲透率；同時，繼續提升內部管理質量，改善經營效率，以使得營業收入和淨利潤長期持續的健康增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
